HIV-1 replication from after cell entry to the nuclear periphery

Current HIV Research

Volumn 5, Issue 3, 2007, Pages 293-299

  Warrilow, David ^a   Harrich, David ^a  

^a QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

Author keywords

HIV; Replication; Restriction factor; Reverse transcription; Uncoating

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; DOUBLE STRANDED DNA; FLUORESCENT DYE; GAG PROTEIN; GENOMIC RNA; PHOSPHOTRANSFERASE; TRIPARTITE MOTIF PROTEIN 5;

ACTIN FILAMENT; BIOCHEMISTRY; CELL ACTIVITY; CELL INFILTRATION; CELL MEMBRANE; CELL NUCLEUS; CELL NUCLEUS MEMBRANE; CYTOPLASM; CYTOSKELETON; ENZYME ACTIVITY; GENE REARRANGEMENT; GENE STRUCTURE; GENETICS; HOST RESISTANCE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTEGRATION; INTRACELLULAR TRANSPORT; LIFE CYCLE; MEMBRANE FUSION; MICROSCOPY; MICROTUBULE; NONHUMAN; PROTEIN DEGRADATION; REVERSE TRANSCRIPTION; REVIEW; VIRION; VIRUS CORE; VIRUS ENVELOPE; VIRUS PATHOGENESIS; VIRUS REPLICATION;

CELL NUCLEUS; CYTOPLASM; HIV INFECTIONS; HIV-1; HUMANS; PHOSPHORYLATION; VIRUS REPLICATION;

EID: 34249065271     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016207780636579     Document Type: Review

References (131)

1. Aiken C. (1997). Pseudotyping human immunodeficiency virus type 1 (HIV-1) by the glycoprotein of vesicular stomatitis virus targets HIV-1 entry to an endocytic pathway and suppresses both the requirement for Nef and the sensitivity to cyclosporin A. Journal of Virology. 71: 5871-5877.
2. Akkina RK, Walton RM, Chen ML, Li QX, Planelles V, Chen IS. (1996). High-efficiency gene transfer into CD34+ cells with a human immunodeficiency virus type 1-based retroviral vector pseudotyped with vesicular stomatitis virus envelope glycoprotein G. Journal of Virology. 70: 2581-2585.
3. Apolloni A, Hooker CW, Mak J, Harrich D. (2003). Human immunodeficiency virus type 1 protease regulation of tat activity is essential for efficient reverse transcription and replication. Journal of Virology. 77: 9912-9921.
4. Arbel N, Genovesio A, Kim KA, Miko S, Perret E, Olivo-Marin JC, Shorte S, Charneau P. (2006). Quantitative four-dimensional tracking of cytoplasmic and nuclear HIV-1 complexes. Nature Methods. 3: 817-824.
5. Ariumi Y, Serhan F, Turelli P, Telenti A, Trono D. (2006). The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription. Retro Virology. 3: 47.
6. Auerbach MR, Shu C, Kaplan A, Singh IR. (2003). Functional characterization of a portion of the Moloney murine leukemia virus gag gene by genetic footprinting. Proceedings of the National Academy of Sciences of the United States of America. 100: 11678-11683.
7. Auewarakul P, Wacharapornin P, Srichatrapimuk S, Chutipongtanate S, Puthavathana P. (2005). Uncoating of HIV-1 requires cellular activation. Virology. 337: 93-101.
8. Berthoux L, Sebastian S, Sokolskaja E, Luban J. (2005). Cyclophilin A is required for TRIM5{alpha}-mediated resistance to HIV-1 in Old World monkey cells. Proceedings of the National Academy of Sciences of the United States of America. 102: 14849-14853.
9. Bishop KN, Holmes RK, Malim MH. (2006). Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. Journal of Virology. 80: 8450-8458.
10. Bishop KN, Holmes RK, Sheehy AM, Davidson NO, Cho SJ, Malim MH. (2004). Cytidine deamination of retroviral DNA by diverse APOBEC proteins. Current Biology. 14: 1392-1396.
11. Briggs JA, Simon MN, Gross J, Krausslich HG, Fuller SD, Vogt VM, Johnson MC. (2004). The stoichiometry of Gag protein in HIV-1. Nature Structural and Molecular Biology. 11: 672-675.
12. Bukrinskaya A, Brichacek B, Mann A, Stevenson M. (1998). Establishment of a functional human immunodeficiency virus type 1 (HIV-1) reverse transcription complex involves the cytoskeleton. Journal of Experimental Medicine. 188: 2113-2125.
13. Bukrinskaya AG, Ghorpade A, Heinzinger NK, Smithgall TE, Lewis RE, Stevenson M. (1996). Phosphorylation-dependent human immunodeficiency virus type 1 infection and nuclear targeting of viral DNA. Proceedings of the National Academy of Sciences of the United States of America. 93: 367-371.
14. Busschots Y, Vercammen J, Emiliani S, Benarous R, Engelborghs Y, Christ F, Debyser Z. (2005). The interaction of LEDGF/p75 with integrase is lenti-virus-specific and promotes DNA binding. Journal of Biological Chemistry. 280: 17841-17847.
15. Campbell EM, Nunez R, Hope TJ. (2004). Disruption of the actin cytoskeleton can complement the ability of Nef to enhance human immunodeficiency virus type 1 infectivity. Journal of Virology. 78: 5745-5755.
16. Carr JM, Davis AJ, Coolen C, Cheney Y, Burrell CJ, Li P. (2006). Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products. Virology. 351: 80-91.
17. Cartier C, Deckert M, Grangeasse C, Trauger R, Jensen F, Bernard A, Cozzone A, Desgranges C, Boyer V. (1997). Association of ERK2 mitogen-activated protein kinase with human immunodeficiency virus particles. Journal of Virology. 71: 4832-4837.
18. Cartier C, Hemonnot B, Gay B, Bardy M, Sanchiz C, Devaux C, Briant L. (2003). Active cAMP-dependent protein kinase incorporated within highly purified HIV- particles is required for viral infectivity and interacts with viral capsid protein. Journal of Biological Chemistry. 278: 35211-35219.
19. Cartier C, Sivard P, Tranchat C, Decimo D, Desgranges C, Boyer V. (1999). Identification of three major phosphorylation sites within HIV-1 capsid. Role of phosphorylation during the early steps of infection. Journal of Biological Chemistry. 274: 19434-19440.
20. Casella CR, Raffini LJ, Panganiban AT. (1997). Pleiotropic mutations in the HIV-1 matrix protein that affect diverse steps in replication. Virology. 228: 294-306.
21. Chen D, Wang M, Zhou S, Zhou Q. (2002). HIV-1 Tat targets microtubules to induce apoptosis, a process promoted by the pro-apoptotic Bcl-2 relative Bim. The EMBO Journal. 21: 6801-6810.
22. Chertova E, Chertov O, Coren LV, Roser JD, Trubey CM, Bess JW, Jr., Sowder RC, 2nd, Barsov E, Hood BL, Fisher RJ, Nagashima Y, Conrads TP, Veenstra TD, Lifson JD, Ott DE. (2006). Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. Journal of Virology. 80: 9039-9052.
23. Chiu YL, Greene WC. (2006). APOBEC3 cytidine deaminases: distinct antiviral actions along the retroviral life cycle. Journal of Biological Chemistry. 281: 8309-8312.
24. Ciuffi A, Llano M, Poeschla E, Hoffmann C, Leipzig J, Shinn P, Ecker JR, Bushman F. (2005). A role for LEDGF/p75 in targeting HIV DNA integration. Nature Medicine. 11: 1287-1289.
25. Crawford S, Goff SP. (1984). Mutations in gag proteins P12 and P15 of Moloney murine leukemia virus block early stages of infection. Journal of Virology. 49: 909-917.
26. Cullen BR. (2006). Role and mechanism of action of the APOBEC3 family of antiretroviral resistance factors. Journal of Virology. 80: 1067-1076.
27. de Mareuil J, Carre M, Barbier P, Campbell GR, Lancelot S, Opi S, Esquieu D, Watkins JD, Prevot C, Braguer D, Peyrot V, Loret EP. (2005). HIV-1 Tat protein enhances microtubule polymerization. Retrovirology. 2: 5.
28. del Alamo M, Rivas G, Mateu MG. (2005). Effect of macromolecular crowding agents on human immunodeficiency virus type 1 capsid protein assembly in vitro. Journal of Virology. 79: 14271-14281.
29. Epie N, Ammosova T, Sapir T, Voloshin Y, Lane WS, Turner W, Reiner O, Nekhai S. (2005). HIV-1 Tat interacts with LIS1 protein. Retrovirology. 2: 6.
30. Farnet CM, Bushman FD. (1997). HIV-1 cDNA integration: requirement of HMG I(Y) protein for function of preintegration complexes in vitro. Cell. 88: 483-492.
31. Farnet CM, Haseltine WA. (1991). Determination of viral proteins present in the human immunodeficiency virus type 1 preintegration complex. Journal of Virology. 65: 1910-1915.
32. Fassati A, Goff SP. (2001). Characterization of intracellular reverse transcription complexes of human immunodeficiency virus type 1. Journal of Virology. 75: 3626-3635.
33. Fassati A, Goff SP. (1999). Characterization of intracellular reverse trancription complexes of Moloney murine leukemia virus. Journal of Virology. 73: 8919-8925.
34. Fitzon T, Leschonsky B, Bieler K, Paulus C, Schroder J, Wolf H, Wagner R. (2000). Proline residues in the HIV-1 NH2-terminal capsid domain: structure determinants for proper core assembly and subsequent steps of early replication. Virology. 268: 294-307.
35. Forshey BM, Aiken C. (2003). Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of Nef with the subviral ribonucleoprotein complex. Journal of Virology. 77: 4409-4414.
36. Forshey BM, Shi J, Aiken C. (2005). Structural requirements for recognition of the human immunodeficiency virus type 1 core during host restriction in owl monkey cells. Journal of Virology. 79: 869-875.
37. Forshey BM, von Schwedler U, Sundquist WI, Aiken C. (2002). Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. Journal of Virology. 76: 5667-5677.
38. Freed EO. (1998). HIV-1 gag proteins: diverse functions in the virus life cycle. Virology. 251: 1-15.
39. Freed EO. (2001). HIV-1 replication. Somatic Cell and Molecular Genetics. 26: 13-33.
40. Freed EO, Englund G, Maldarelli F, Martin MA. (1997). Phosphorylation of residue 131 of HIV-1 matrix is not required for macrophage infection. Cell. 88: 171-173; discussion 173-174.
41. Gallay P, Swingler S, Aiken C, Trono D. (1995). HIV-1 infection of nondividing cells: C-terminal tyrosine phosphorylation of the viral matrix protein is a key regulator. Cell. 80: 379-388.
42. Gallay P, Swingler S, Song J, Bushman F, Trono D. (1995). HIV nuclear import is governed by the phosphotyrosine-mediated binding of matrix to the core domain of integrase. Cell. 83: 569-576.
43. Goff SP. (2001). Intracellular trafficking of retroviral genomes during the early phase of infection: viral exploitation of cellular pathways. The Journal of Gene Medicine. 3: 517-528.
44. Goncalves J, Korin Y, Zack J, Gabuzda D. (1996). Role of Vif in human immunodeficiency virus type 1 reverse transcription. Journal of Virology. 70: 8701-8709.
45. Grewe C, Beck A, Gelderblom HR. (1990). HIV: early virus-cell interactions. Journal of Acquired Immune Deficiency Syndromes. 3: 965-974.
46. Gross I, Hohenberg H, Krausslich HG. (1997). In vitro assembly properties of purified bacterially expressed capsid proteins of human immunodeficiency virus. European Journal of Biochemistry. 249: 592-600.
47. Hamamoto S, Nishitsuji H, Amagasa T, Kannagi M, Masuda T. (2006). Identification of a novel human immunodeficiency virus type 1 integrase interactor, Gemin2, that facilitates efficient viral cDNA synthesis in vivo. Journal of Virology. 80: 5670-5677.
48. Harrich D, Ulich C, Garcia-Martinez LF, Gaynor RB. (1997). Tat is required for efficient HIV-1 reverse transcription. The EMBO Journal. 16: 1224-1235.
49. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, Watt IN, Neuberger MS, Malim MH. (2003). DNA deamination mediates innate immunity to retroviral infection. Cell. 113: 803-809.
50. Hatanaka M, Twiddy E, Gilden RV. (1972). Protein kinase associated with RNA tumor viruses and other budding RNA viruses. Virology. 47: 536-538.
51. Hatziioannou T, Perez-Caballero D, Cowan S, Bieniasz PD. (2005). Cyclophilin interactions with incoming human immunodeficiency virus type 1 capsids with opposing effects on infectivity in human cells. Journal of Virology. 79: 176-183.
52. Henzler T, Harmache A, Herrmann H, Spring H, Suzan M, Audoly G, Panek T, Bosch V. (2001). Fully functional, naturally occurring and C-terminally truncated variant human immunodeficiency virus (HIV) Vif does not bind to HIV Gag but influences intermediate filament structure. The Journal of General Virology. 82: 561-573.
53. Hooker CW, Harrich D. (2003). The first strand transfer reaction of HIV-1 reverse transcription is more efficient in infected cells than in cell-free natural endogenous reverse transcription reactions. The Journal of Clinical Virology. 26: 229-238.
54. Houts GE, Miyagi M, Ellis C, Beard D, Watson KF, Beard JW. (1978). Protein kinase from avian myeloblastosis virus. Journal of Virology. 25: 546-552.
55. Hsu HW, Schwartzberg P, Goff SP. (1985). Point mutations in the P30 domain of the gag gene of Moloney murine leukemia virus. Virology. 142: 211-214.
56. Huang Y, Wang J, Shalom A, Li Z, Khorchid A, Wainberg MA, Kleiman L. (1997). Primer tRNA3Lys on the viral genome exists in unextended and two-base extended forms within mature human immunodeficiency virus type 1. Journal of Virology. 71: 726-728.
57. Iordanskiy S, Berro R, Altieri M, Kashanchi F, Bukrinsky M. (2006). Intracytoplasmic maturation of the human immunodeficiency virus type 1 reverse transcription complexes determines their capacity to integrate into chromatin. Retrovirology. 3: 4.
58. Isel C, Ehresmann C, Keith G, Ehresmann B, Marquet R. (1995). Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/ tRNA(3Lys) (template/primer). Journal of Molecular Biology. 247: 236-250.
59. Jacque JM, Mann A, Enslen H, Sharova N, Brichacek B, Davis RJ, Stevenson M. (1998). Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. The EMBO Journal. 17: 2607-2618.
60. Kabouridis PS. (2006). Lipid rafts in T cell receptor signalling. Molecular Membrane Biology. 23: 49-57.
61. Kao S, Khan MA, Miyagi E, Plishka R, Buckler-White A, Strebel K. (2003). The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. Journal of Virology. 77: 11398-11407.
62. Karageorgos L, Li P, Burrell C. (1993). Characterization of HIV replication complexes early after cell-to-cell infection. AIDS Research and Human Retroviruses. 9: 817-823.
63. Kaushik R, Ratner L. (2004). Role of human immunodeficiency virus type 1 matrix phosphorylation in an early postentry step of virus replication. Journal of Virology. 78: 2319-2326.
64. Keckesova Z, Ylinen LM, Towers GJ. (2006). Cyclophilin A renders human immunodeficiency virus type 1 sensitive to Old World monkey but not human TRIM5 alpha antiviral activity. Journal of Virology. 80: 4683-4690.
65. Khan M, Garcia-Barrio M, Powell MD. (2001). Restoration of wild-type infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription. Journal of Virology. 75: 12081-12087.
66. Koh K, Miyaura M, Yoshida A, Sakurai A, Fujita M, Adachi A. (2000). Cell-dependent gag mutants of HIV-1 are crucially defective at the stage of uncoating/reverse transcription in non-permissive cells. Microbes and Infection. 2: 1419-1423.
67. Komano J, Miyauchi K, Matsuda Z, Yamamoto N. (2004). Inhibiting the Arp2/ 3 complex limits infection of both intracellular mature vaccinia virus and primate lentiviruses. Molecular Biology of the Cell. 15: 5197-5207.
68. Kootstra NA, Munk C, Tonnu N, Landau NR, Verma IM. (2003). Abrogation of postentry restriction of HIV-1-based lentiviral vector transduction in simian cells. Proceedings of the National Academy of Sciences of the United States of America. 100: 1298-1303.
69. Kotov A, Zhou J, Flicker P, Aiken C. (1999). Association of Nef with the Human Inummodeficiency Virus Type 1 Core. Journal of Virology. 73: 8824-8830.
70. Lanman J, Lam TT, Emmett MR, Marshall AG, Sakalian M, Prevelige PE, Jr. (2004). Key interactions in HIV-1 maturation identified by hydrogen-deuterium exchange. Nature Structural and Molecular Biology. 11: 676-677.
71. Lecossier D, Bouchonnet F, Clavel F, Hance AJ. (2003). Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science. 300: 1112.
72. Leung J, Yueh A, Appah FS, Jr., Yuan B, de los Santos K, Goff SP. (2006). Interaction of Moloney murine leukemia virus matrix protein with IQGAP. The EMBO Journal. 25: 2155-2166.
73. Li Y, Li X, Stremlau M, Lee M, Sodroski J. (2006). Removal of arginine 332 allows human TRIM5alpha to bind human immunodeficiency virus capsids and to restrict infection. Journal of Virology. 80: 6738-6744.
74. Liddament MT, Brown WL, Schumacher AJ, Harris RS. (2004). APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Current Biology. 14: 1385-1391.
75. Liu H, Wu X, Newman M, Shaw GM, Hahn BH, Kappes JC. (1995). The Vif protein of human and simian immunodeficiency viruses is packaged into virions and associates with viral core structures. Journal of Virology. 69: 7630-7638.
76. Llano M, Saenz DT, Meehan A, Wongthida P, Peretz M, Walker WH, Teo W, Poeschla EM. (2006). An essential role for LEDGF/p75 in HIV integration. Science. 314: 461-464.
77. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. (2003). Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature. 424: 99-103.
78. Mariani R, Chen D, Schrofelbauer B, Navarro F, Konig R, Bollman B, Munk C, Nymark-McMahon H, Landau NR. (2003). Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell. 114: 21-31.
79. Marin M, Rose KM, Kozak SL, Kabat D. (2003). HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Medicine. 9: 1398-1403.
80. McDonald D, Vodicka MA, Lucero G, Svitkina TM, Borisy GG, Emerman M, Hope TJ. (2002). Visualization of the intracellular behavior of HIV in living cells. The Journal of Cell Biology. 159: 441-452.
81. Miller MD, Farnet CM, Bushman FD. (1997). Human immunodeficiency virus type 1 preintegration complexes: studies of organization and composition. Journal of Virology. 71: 5382-5390.
82. Naldini L, Blomer U, Galley P, Ory D, Mulligan R, Gage FH, Verma IM, Trono D. (1996). In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science. 272: 263-267.
83. Narayan S, Young JA. (2004). Reconstitution of retroviral fusion and uncoating in a cell-free system. Proceedings of the National Academy of Sciences of the United States of America. 101: 7721-7726.
84. Nermut MV, Fassati A. (2003). Structural analyses of purified human immunodeficiency virus type 1 intracellular reverse transcription complexes. Journal of Virology. 77: 8196-8206.
85. Newman EN, Holmes RK, Craig HM, Klein KC, Lingappa JR, Malim MH, Sheehy AM. (2005). Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology. 15: 166-170.
86. Ohagen A, Gabuzda D. (2000). Role of Vif in stability of the human immunodeficiency virus type 1 core. Journal of Virology. 74: 11055-11066.
87. Ott DE, Coren LV, Johnson DG, Kane BP, Sowder RC, 2nd, Kim YD, Fisher RJ, Zhou XZ, Lu KP, Henderson LE. (2000). Actin-binding cellular proteins inside human immunodeficiency virus type 1. Virology. 266: 42-51.
88. Petit C, Giron ML, Tobaly-Tapiero J, Bittoun P, Real E, Jacob Y, Tordo N, De The H, Saib A. (2003). Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. Journal of Cell Science. 116: 3433-3442.
89. Reicin AS, Ohagen A, Yin L, Hoglund S, Goff SP. (1996). The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. Journal of Virology. 70: 8645-8652.
90. Reiser J, Harmison G, Kluepfel-Stahl S, Brady RO, Karlsson S, Schubert M. (1996). Transduction of nondividing cells using pseudotyped defective high-titer HIV type 1 particles. Proceedings of the National Academy of Sciences of the United States of America. 93: 15266-15271.
91. Reymond A, Meroni G, Fantozzi A, Merla G, Cairo S, Luzi L, Riganelli D, Zanaria E, Messali S, Cainarca S, Guffanti A, Minucci S, Pelicci PG, Ballabio A. (2001). The tripartite motif family identifies cell compartments. The EMBO Journal. 20: 2140-2151.
92. Rosok MJ, Watson KF. (1979). Fractionation of two protein kinases from avian myeloblastosis virus and characterization of the protein kinase activity preferring basic phosphoacceptor proteins. Journal of Virology. 29: 872-880.
93. Schmitz C, Marchant D, Neil SJ, Aubin K, Reuter S, Dittmar MT, McKnight A. (2004). Lv2, a novel postentry restriction, is mediated by both capsid and envelope. Journal of Virology. 78: 2006-2016.
94. Scholz I, Arvidson B, Huseby D, Barklis E. (2005). Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. Journal of Virology. 79: 1470-1479.
95. Schwartz O, Marechal V, Danos O, Heard JM. (1995). Human immunodeficiency virus type 1 Nef increases the efficiency of reverse transcription in the infected cell. Journal of Virology. 69: 4053-4059.
96. Sebastian S, Luban J. (2005). TRIM5alpha selectively binds a restriction-sensitive retroviral capsid. Retro Virology. 2: 40.
97. Sen A. (1981). Purified low-molecular-weight protein kinase from murine sarcoma virus particles catalyzes tyrosine phosphorylation endogenously but phosphorylates cellular proteins at serine. Journal of Virology. 39: 612-624.
98. Sen A, Todaro GJ. (1979). A murine sarcoma virus-associated protein kinase: interaction with actin and microtubular protein. Cell. 17: 347-356.
99. Sen A, Todaro GJ, Blair DG, Robey WG. (1979). Thermolabile protein kinase molecules in a temperature-sensitive murine sarcoma virus pseudotype. Proceedings of the National Academy of Sciences of the United States of America. 76: 3617-3621.
100. Sheehy AM, Gaddis NC, Choi JD, Malim MH. (2002). Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature. 418: 646-650.
101. Sheehy AM, Gaddis NC, Malim MH. (2003). The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine. 9: 1404-1407.
102. Shimano R, Iida S, Fukumori T, Yamamoto Y, Kawamura M, Furuta RA, Adachi A. (1998). Inhibition of HIV replication by capsid mutant C6b. Biochemical and Biophysical Research Communications. 242: 313-316.
103. Sokolskaja E, Berthoux L, Luban J. (2006). Cyclophilin A and TRIM5alpha independently regulate human immunodeficiency virus type 1 infectivity in human cells. Journal of Virology. 80: 2855-2862.
104. Sokolskaja E, Luban J. (2006). Cyclophilin, TRIM5, and innate immunity to HIV-1. Current Opinion in Microbiology. 9: 404-408.
105. Sokolskaja E, Sayah DM, Luban J. (2004). Target cell cyclophilin A modulates human immunodeficiency virus type 1 infectivity. Journal of Virology. 78: 12800-12808.
106. Spearman P, Horton R, Ratner L, Kuli-Zade I. (1997). Membrane binding of human immunodeficiency virus type 1 matrix protein in vivo supports a conformational myristyl switch mechanism. Journal of Virology. 71: 6582-6592.
107. Stremlau M, Perron M, Lee M, Li Y, Song B, Javanbakht H, Diaz-Griffero F, Anderson DJ, Sundquist WI, Sodroski J. (2006). Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5 {alpha} restriction factor. Proceedings of the National Academy of Sciences of the United States of America.
108. Stremlau M, Perron M, Welikala S, Sodroski J. (2005). Species-specific variation in the B30.2(SPRY) domain of TRIM5alpha determines the potency of human immunodeficiency virus restriction. Journal of Virology. 79: 3139-3145.
109. Stremlau M, Song B, Javanbakht H, Perron M, Sodroski J. (2006). Cyclophilin A: an auxiliary but not necessary cofactor for TRIM5alpha restriction of HIV-1. Virology. 351: 112-120.
110. Swingler S, Gallay P, Camaur D, Song J, Abo, A, Trono D. (1997). The Nef protein of human immunodeficiency virus type 1 enhances serine phosphorylation of the viral matrix. Journal of Virology. 71: 4372-4377.
111. Tang S, Murakami T, Cheng N, Steven AC, Freed EO, Levin JG. (2003). Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. Journal of Virology. 77: 12592-12602.
112. Telesnitsky A, Goff SP. (1997). Reverse transcriptase mid the generation of retroviral DNA. In: Coffin JM, Huges SH, Varmus HE Eds, Retroviruses. Cold Spring Harbour, N.Y. Cold Spring Harbor Laboratory Press, pp. 121-160.
113. Thomas EK, Connelly RJ, Pennathur S, Dubrovsky L, Haffar OK, Bukrinsky MI. (1996). Anti-idiotypic antibody to the V3 domain of gp120 binds to vimentin: a possible role of intermediate filaments in the early steps of HIV-1 infection cycle. Viral Immunology. 9: 73-87.
114. Towers GJ, Hatziioannou T, Cowan S, Goff SP, Luban J, Bieniasz PD. (2003). Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. Nature Medicine. 9: 1138-1143.
115. Tsiapalis CM. (1977). Protein kinase and phosphoproteins of avian myeloblastosis virus. Journal of Virology. 21: 843-848.
116. Tsurutani N, Kubo M, Maeda Y, Ohashi T, Yamamoto N, Kannagi M, Masuda T. (2000). Identification of critical amino acid residues in human immunodeficiency virus type 1 IN required for efficient proviral DNA formation at steps prior to integration in dividing and nondividing cells. Journal of Virology. 74: 4795-4806.
117. Turelli P, Doucas V, Craig E, Mangeat B, Klages N, Evans R, Kalpana G, Trono D. (2001). Cytoplasmic recruitment of INI1 and PML on incoming HIV preintegration complexes: interference with early steps of viral replication. Molecular Cell. 7: 1245-1254.
118. Ulich C, Dunne A, Parry E, Hooker CW, Gaynor RB, Harrich D. (1999). Functional domains of Tat required for efficient human immunodeficiency virus type 1 reverse transcription. Journal of Virology. 73: 2499-2508.
119. Van Maele B, Busschots K, Vandekerckhove L, Christ F, Debyser Z. (2006). Cellular co-factors of HIV-1 integration. Trends in Biochemical Sciences. 31: 98-105.
120. Vogt PK. (1997). Historical introduction to the general properties of retroviruses. In: Coffin JM, Huges SH, Varmus HE Eds, Retroviruses. Cold Spring Harbour, N.Y. Cold Spring Harbor Laboratory Press, pp, 4.
121. Welker R, Hohenberg H, Tessmer U, Huckhagel C, Krausslich HG. (2000). Biochemical and structural analysis of isolated mature cores of human immunodeficiency virus type 1. Journal of Virology. 74: 1168-1177.
122. Wu X, Anderson JL, Campbell EM, Joseph AM, Hope TJ. (2006). Proteasome inhibitors uncouple rhesus TRIM5alpha restriction of HIV-1 reverse transcription and infection. Proceedings of the National Academy of Sciences of the United States of America. 103: 7465-7470.
123. Wu X, Liu H, Xioa, H, Conway JA, Hehl E, Kalpana GV, Prasad V, Kappes JC. (1999). Human immunodeficiency virus type 1 integrase protein promotes reverse transcription through specific interactions with the nucleoprotein reverse transcription complex. Journal of Virology. 73: 2126-2135.
124. Yamashita M, Emerman M. (2006). Retroviral infection of non-dividing cells: old and new perspectives. Virology. 344: 88-93.
125. Yap MW, Dodding NT, Stoye JP. (2006). Trim-cyclophilin A fusion proteins can restrict human immunodeficiency virus type 1 infection at two distinct phases in the viral life cycle. Journal of Virology. 80: 4061-4067.
126. Yap MW, Nisole S, Stoye JP. (2005). A single amino acid change in the SPRY domain of human Trim5alpha leads to HIV-1 restriction. Current Biology. 15: 73-78.
127. Yu X, Yu Y, Liu B, Luo K, Kong W, Mao P, Yu XF. (2003). Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science. 302: 1056-1060.
128. Yuan B, Fassati A, Yueh A, Goff SP. (2002). Characterization of Moloney murine leukemia virus p12 mutants blocked during early events of infection. Journal of Virology. 76: 10801-10810.
129. Zhang H, Dornadula G, Orenstein J, Pomerantz RJ. (2000). Morphologic changes in human immunodeficiency virus type 1 virions secondary to intravirion reverse transcription: evidence indicating that reverse transcription may not take place within the intact viral core. Journal of Human Virology. 3: 165-172.
130. Zhang H, Yang B, Pomerantz RJ, Zhang C, Arunachalam SC, Gao L. (2003). The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature. 424: 94-98.
131. Zheng YH, Irwin D, Kurosu T, Tokunaga K, Sata T, Peterlin BM. (2004). Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. Journal of Virology. 78: 6073-6076.